New antibiogram!

/

The GLA antibiogram for calendar year 2021 is here! Some highlights:

For Gram-negative rods in the hospital setting:

  • Carbapenem-resistant Enterobacteriaceae remain relatively uncommon at GLA

  • Amikacin remains most active agent vs. multi-drug resistant Gram-negative rod infections at GLA, despite P. aeruginosa susceptibility decreasing somewhat (2020: 100%; 2021: 92%)

  • If specific coverage for Pseudomonas is warranted, piperacillin-tazobactam provides more coverage (87%) than cefepime (61%) and meropenem (61%), though meropenem and ertapenem have better coverage against non-Pseudomonas Gram-negative nosocomial isolates

  • Fluoroquinolone susceptibility versus most nosocomial Gram-negative organisms remains relatively poor and ceftriaxone susceptibility among urine nosocomial Gram-negatives is variable.

  • For Gram-negative rods in the outpatient setting:

    • Cefazolin susceptibility among common urinary Enterobacteriaceae is not readily captured but susceptibility rates among other beta-lactams remain relatively stable

    • Fluoroquinolone and TMP-SMX susceptibilities remain largely stable

  • Key trends among Gram-positive isolates:

    • MRSA 56% of nosocomial non-blood isolates, 47% of nosocomial blood isolates

    • MRSA ~40% outpatient non-blood isolates

    • Doxycycline susceptibility remains stable among non-blood S. aureus isolates (83% nosocomial, 90% outpatient)